Tvardi Therapeutics (TVRD) Return on Capital Employed (2014 - 2026)
Tvardi Therapeutics (TVRD) posted Return on Capital Employed of 166.48% for Q1 2026, down 52.52% sequentially from 109.15% in Q4 2025, and down 8839.0% YoY from 1.91% in Q1 2025.
Tvardi Therapeutics (TVRD) Return on Capital Employed (2014 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Return on Capital Employed for 13 years, with the latest figure at 166.48% in Q1 2026.
- Quarterly Return on Capital Employed fell 8839.0% year-over-year to 166.48% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 166.48% (down 8839.0% YoY) and the FY2025 annual result came in at 118.39%, down 7832.0% from the prior year.
- Return on Capital Employed declined to 166.48% in Q1 2026 per TVRD's latest filing, from 109.15% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 32.85% in Q2 2022 and troughed at 166.48% in Q1 2026.
- A 5-year average of 100.52% and a median of 98.74% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed jumped 5490 bps in 2025, then tumbled 8839 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 50.19% in 2022, then slumped by 155 bps to 127.89% in 2023, then retreated by 27 bps to 162.1% in 2024, then jumped by 33 bps to 109.15% in 2025, then slumped by 53 bps to 166.48% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 166.48%, 109.15%, and 98.74% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 7.88% |
| 10 | Tvardi Therapeutics | 17.40 Mn | 17.40 Mn | - | -216.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -166.48% |
| Dec 31, 2025 | -109.15% |
| Sep 30, 2025 | -98.74% |
| Jun 30, 2025 | -96.84% |
| Mar 31, 2025 | -78.09% |
| Dec 31, 2024 | -162.10% |
| Sep 30, 2024 | -144.83% |
| Jun 30, 2024 | -145.93% |
| Mar 31, 2024 | -132.98% |
| Dec 31, 2023 | -127.89% |
| Sep 30, 2023 | -117.86% |
| Jun 30, 2023 | -97.27% |
| Mar 31, 2023 | -57.77% |
| Dec 31, 2022 | -50.19% |
| Sep 30, 2022 | -46.78% |
| Jun 30, 2022 | -32.85% |
| Mar 31, 2022 | -43.02% |
| Dec 31, 2021 | -40.78% |
| Sep 30, 2021 | 10.94% |
| Jun 30, 2021 | 3.10% |